PT  - JOURNAL ARTICLE
AU  - Hemsinlioglu, Cansu
AU  - Pelit, Nil Banu
AU  - Yalcin, Koray
AU  - Gunaydın, Omur Selin
AU  - Sahin, Nihal Ozturk
AU  - Karagacli, Esra Savas
AU  - Elibol, Omer
AU  - Demir, Sefa Onur
AU  - Safak, Evren
AU  - Turan, Raife Dilek
AU  - Celebi, Goncagul
AU  - Kocaoglu, Miyase Ezgi
AU  - Karakus, Gozde Sir
AU  - Yurtsever, Bulut
AU  - Tastan, Cihan
AU  - Abanuz, Selen
AU  - Cakirsoy, Didem
AU  - Kancagi, Derya Dilek
AU  - Torun, Zeynep
AU  - Seyis, Utku
AU  - Elek, Muhammer
AU  - Zengin, Rehile
AU  - Kocagoz, Ayse Sesin
AU  - Cuhadaroglu, Caglar
AU  - Birgen, Nur
AU  - Ratip, Siret
AU  - Ovali, Ercument
TI  - THE EFFECTIVENESS OF ACB-IP 1.0 UNIVERSAL PATHOGEN FREE CONCENTRATED COCKTAIL CONVALESCENT PLASMA IN COVID-19 INFECTION
AID  - 10.1101/2021.03.05.21251413
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.05.21251413
4099  - http://medrxiv.org/content/early/2021/03/22/2021.03.05.21251413.short
4100  - http://medrxiv.org/content/early/2021/03/22/2021.03.05.21251413.full
AB  - Introduction The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.Methods In this study, ACB-IP 1.0 convalescent plasma product was prepared as follows; first, convalescent plasma was collected from different donors, then pathogen-inactivation was carried-out, and isohemagglutinins were cryodepleted, respectively. Finally, concentrated convalescent plasma product was pooled and stored until use.A total of sixteen patients were treated with two different convalescent plasma products. Nine patients were treated with standard single donor convalescent plasma and seven were treated with pathogen-free, concentrated, pooled convalescent plasma (ACB-IP 1.0) between 01 April 2020 and 31 December 2020.The outcomes of these two plasma products were compared regarding SARS-CoV2 antibody titers, neutralizing antibody activities, length of hospitalization and mortality rates.Results Five out of six single donor plasma SARS-CoV2 antibody titers remained below 12 s/co, but the antibody titers of all ACB-IP 1.0 plasma were above 12 s/co. SARS-CoV2 total antibody titers of ACB-IP 1.0 plasma were statistically higher than the antibody titers of single donor plasma. Mean total plasma neutralizing antibody activity of ACB-IP 1.0 plasma (1.5421) was found statistically higher than single donor plasma (0.9642) in 1:256 dilution (ρ=0.0087)The mortality rate of the patients treated with ACB-IP 1.0 plasma showed statistically lower (p: 0,033) than the patients treated with single donor plasma. The administration of either single donor plasma or ACB-IP 1.0 plasma to the patients within eight days significantly shortened the length of hospitalization compared to administration of either plasma to the patients later than eight days (ρ= 0,0021)Discussion Pathogen-free, concentrated, pooled convalescent plasma may resolve the bias in SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic. This study indicates that ACB-IP 1.0 may be a superior product compared to standard single donor plasma.(Patent Application No: PY2020-00232)Competing Interest StatementAcibadem Healthcare Group provides patients with gene therapy products and tissue engineering in the field of cellular therapy all of the 27 authors are affiliated with the funder.Clinical TrialNCT04769245Funding StatementAll fundings in the work was supported by TUBITAKAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approval of Acibadem University ethics committee (Approval No: 2020-06/02)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available via Acibadem Hospital electronic medical records system.